Qin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Qin Deng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Daixing Hu
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationDan Guo
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationWantao Ju
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China
1 shared publication- Yanjun Liu
Section for Gastrointestinal Surgery, Department of General Surgery, The Third People’s Hospital of Chengdu, Clinical College of Southwest Jiao Tong University, The Affiliated Hospital of Southwest Jiao Tong University, Chengdu, China
1 shared publication Yaru Yang
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationYujing Tang
School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 10 March 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-6
Thyroidectomy, especially total thyroidectomy, adversely affects erectile function in men
To evaluate the frequency of erectile dysfunction in male patients who undergo thyroidectomy using the International Index of Erectile Function (IIEF-5), and explore possible risk factors. 163 male patients who undergo partial, unilateral or bilateral thyroidectomy between December 2021 and September 2022 were retrospectively studied. The IIEF-5 questionnaires were completed 6 and 12 months after surgery, and patients who reported erectile dysfunction (ED) before surgery were not included. Sociodemographic factors (age, education status, and employment status) and health behavior (smoking and alcohol consumption) were also recorded. The above factors and clinical data were included for statistical analysis. Fifty-five patients underwent total thyroidectomy (TT), 67 underwent hemithyroidectomy (HT), and 41 underwent partial thyroidectomy (PT). Six months after surgery, 33 patients (60%) in the TT group, 38 (56.7%) patients in the HT group, and 11(26.8%) patients in the PT group reported ED. The lowest scores were observed in the TT group (TT: 19.22 ± 3.895, HT: 20.67 ± 2.836, PT: 21.98 ± 1.651, P < 0.05). At the 12-month postoperative visit, the mean IIEF-5 scores were better in the HT and PT groups and worse in the TT group (TT: 18.36 ± 4.335, HT: 21.40 ± 2.692, PT: 22.54 ± 1.206, P < 0.05). Binary logistic regression analysis revealed that age and extent of resection significantly affected the onset of postoperative ED. Thyroidectomy, especially the total thyroidectomy, adversely affects erectile function. In addition to the operative procedure, age was also found to be significantly associated with postoperative ED.
- 10 March 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-6
Open AccessThyroidectomy, especially total thyroidectomy, adversely affects erectile function in men
To evaluate the frequency of erectile dysfunction in male patients who undergo thyroidectomy using the International Index of Erectile Function (IIEF-5), and explore possible risk factors. 163 male patients who undergo partial, unilateral or bilateral thyroidectomy between December 2021 and September 2022 were retrospectively studied. The IIEF-5 questionnaires were completed 6 and 12 months after surgery, and patients who reported erectile dysfunction (ED) before surgery were not included. Sociodemographic factors (age, education status, and employment status) and health behavior (smoking and alcohol consumption) were also recorded. The above factors and clinical data were included for statistical analysis. Fifty-five patients underwent total thyroidectomy (TT), 67 underwent hemithyroidectomy (HT), and 41 underwent partial thyroidectomy (PT). Six months after surgery, 33 patients (60%) in the TT group, 38 (56.7%) patients in the HT group, and 11(26.8%) patients in the PT group reported ED. The lowest scores were observed in the TT group (TT: 19.22 ± 3.895, HT: 20.67 ± 2.836, PT: 21.98 ± 1.651, P < 0.05). At the 12-month postoperative visit, the mean IIEF-5 scores were better in the HT and PT groups and worse in the TT group (TT: 18.36 ± 4.335, HT: 21.40 ± 2.692, PT: 22.54 ± 1.206, P < 0.05). Binary logistic regression analysis revealed that age and extent of resection significantly affected the onset of postoperative ED. Thyroidectomy, especially the total thyroidectomy, adversely affects erectile function. In addition to the operative procedure, age was also found to be significantly associated with postoperative ED.
- Open Access
- 30 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1469830
The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy
Cancer, the world’s second leading cause of death after cardiovascular diseases, is characterized by hallmarks such as uncontrolled cell growth, metastasis, angiogenesis, hypoxia, and resistance to therapy. Autophagy, a cellular process that can both support and inhibit cancer progression, plays a critical role in cancer development and progression. This process involves the formation of autophagosomes that ultimately fuse with lysosomes to degrade cellular components. A key regulator of this process is Sirtuin 1 (SIRT1), which significantly influences autophagy. This review delves into the role of SIRT1 in modulating autophagy and its broader impacts on carcinogenesis. SIRT1 regulates crucial autophagy mediators, such as AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR), effectively promoting or suppressing autophagy. Beyond its direct effects on autophagy, SIRT1’s regulatory actions extend to other cell death processes, including apoptosis and ferroptosis, thereby influencing tumor cell proliferation, metastasis, and chemotherapy responses. These insights underscore the complex interplay between SIRT1 and autophagy, with significant implications for cancer therapy. Targeting SIRT1 and its associated pathways presents a promising strategy to manipulate autophagy in cancer treatment. This review underscores the potential of SIRT1 as a therapeutic target, opening new avenues for enhancing cancer treatment efficacy.
- 30 September 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1469830
Open AccessThe role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy
Cancer, the world’s second leading cause of death after cardiovascular diseases, is characterized by hallmarks such as uncontrolled cell growth, metastasis, angiogenesis, hypoxia, and resistance to therapy. Autophagy, a cellular process that can both support and inhibit cancer progression, plays a critical role in cancer development and progression. This process involves the formation of autophagosomes that ultimately fuse with lysosomes to degrade cellular components. A key regulator of this process is Sirtuin 1 (SIRT1), which significantly influences autophagy. This review delves into the role of SIRT1 in modulating autophagy and its broader impacts on carcinogenesis. SIRT1 regulates crucial autophagy mediators, such as AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR), effectively promoting or suppressing autophagy. Beyond its direct effects on autophagy, SIRT1’s regulatory actions extend to other cell death processes, including apoptosis and ferroptosis, thereby influencing tumor cell proliferation, metastasis, and chemotherapy responses. These insights underscore the complex interplay between SIRT1 and autophagy, with significant implications for cancer therapy. Targeting SIRT1 and its associated pathways presents a promising strategy to manipulate autophagy in cancer treatment. This review underscores the potential of SIRT1 as a therapeutic target, opening new avenues for enhancing cancer treatment efficacy.